No Data
Crinetics Pharmaceuticals Is Maintained at Outperform by Baird
Crinetics Pharmaceuticals Is Maintained at Outperform by Baird
Crinetics Pharmaceuticals Price Target Raised to $62.00/Share From $52.00 by Baird
Crinetics Pharmaceuticals Price Target Raised to $62.00/Share From $52.00 by Baird
Baird: Maintaining the Crinetics Pharmaceuticals (CRNX.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $52.00 to $62.00.
Baird: Maintaining the Crinetics Pharmaceuticals (CRNX.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $52.00 to $62.00.
Cantor Fitzgerald Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $75
Cantor Fitzgerald analyst Joshua Schimmer maintains $Crinetics(CRNX.US)$ with a buy rating, and adjusts the target price from $65 to $75.According to TipRanks data, the analyst has a success rate of 5
Baird Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $62
Baird analyst Brian Skorney maintains $Crinetics(CRNX.US)$ with a buy rating, and adjusts the target price from $52 to $62.According to TipRanks data, the analyst has a success rate of 41.7% and a tot
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and BioMarin Pharmaceutical (BMRN)